我們已在上線！進一步了解

Iovance Biotherapeutics

IOVA

市值 US$61.7億

13.62 USD

-1.10

7.47%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

13.63

+0.01

0.07%

1天

-7.47%

5天

-6.07%

1個月

37.99%

3個月

192.27%

6個月

258.42%

今年迄今

440.48%

1年

508.04%

5年

-46.67%

10年

112.81%

關於： Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

員工： 975

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 50%

中性 41.2%

負面 8.8%

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 111,615 shares of Iovance's common stock to twenty-one new, non-executive employees.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Top 3 Health Care Stocks That May Collapse In Q4

As of Oct. 5, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Collapse In Q4

Iovance: Buy Now Before Many Growth Catalysts Kick In

Iovance raised 2026 revenue guidance to $410–$420 million as Amtagvi adoption accelerates, supported by expanding treatment access, greater physician awareness, and faster manufacturing. Frontline melanoma trials, lung cancer development, and international expansion could broaden Amtagvi's market by at least an order of magnitude from the current peak sales expectation of $1B. Internal manufacturing supports improving margins and narrowing losses. I project gross margins reaching 65–70%, although continued cash burn and potential dilution remain risks.

Iovance: Buy Now Before Many Growth Catalysts Kick In

Zacks Investment Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026.

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Zacks Investment Research

IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026

Iovance hits a 52-week high after raising its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.

IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026

Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?

Shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) are trading flat Wednesday morning, taking a breather after Tuesday's surge which pushed the stock to a new 52-week high.

Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?

Zacks Investment Research

Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?

Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?

Iovance Biotherapeutics' Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares are trading higher on Tuesday as the company raises full-year 2026 revenue guidance, bucking a -0.8% slide in the Healthcare sector even as the S&P 500 is down 0.10%.

Iovance Biotherapeutics' Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today raised its full year 2026 total revenue guidance range to $410 to $420 million, driven by strong U.S. demand for Amtagvi® (lifileucel) and Proleukin.

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

查看新聞排名

價格圖表採用Lightweight Charts™實作